What's new in the management of psoriasis?

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 2, 2009, Pages 103-117

  Kinney, M A ^a   Feldman, S R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Biological products; Compliance; Dermatology; Health services research; Patient education; Psoriasis, diagnosis; Psoriasis, drug therapy

Indexed keywords

ABT 874; ADALIMUMAB; ADAPALENE; ALEFACEPT; CALCIPOTRIOL; CALCITRIOL; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; KERATOLYTIC AGENT; METHOTREXATE; PARICALCITOL; PIMECROLIMUS; PLACEBO; RETINOID; TACALCITOL; TACROLIMUS; TAR; TAZAROTENE; USTEKINUMAB;

ALOPECIA; ARTHRALGIA; ARTHRITIS; BRAIN PSEUDOTUMOR; CARDIOVASCULAR RISK; CHEILITIS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUNSELING; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSLIPIDEMIA; FLU LIKE SYNDROME; HEPATITIS; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MUCOCUTANEOUS D; MYALGIA; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; PULSED DYE LASER; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKELETON MALFORMATION; SMOKING; SUPPORT GROUP; TERATOGENESIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 67649515045     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Bos JD, Spuls PI. Topical treatments in psoriasis: today and tomorrow. Clin Dermatol 2008;26:432-437
2. Storm A, Benfeldt E, Andersen SE, Serup J. Basic drug information given by physicians is deficient, and patients' knowledge low. J Dermatolog Treat 2008;1-4.
3. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer AB Jr, Clark AR. The physical, psychological and social impact of psoriasis. J Health Psychol 1997;2:525-537 (Pubitemid 27475070)
4. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-414 (Pubitemid 38469243)
5. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006;55:607-13. (Pubitemid 44436629)
6. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006;20:370-9.
7. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008;59:27-33.
8. Awadalla FC, Yentzer B, Balkrishnan R, Feldman SR. A role for denial in poor adherence to psoriasis treatment. J Dermatolog Treat 2007;18:324-325 (Pubitemid 350223200)
9. Feldman SR. Why don't patients get better? The three 'nons'. J Dermatolog Treat 2007;18:136-137
10. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007;143:912-915 (Pubitemid 47076491)
11. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-1016
12. Feldman SR. Top 10 psoriasis treatment tips. G Ital Dermatol Venereol 2006;141:55-62.
13. Uhas AA, Camacho FT, Feldman SR, Balkrishnan R. The Relationship Between Physician Friendliness and Caring, and Patient Satisfaction: Findings from an Internet-Based Survey. The Patient 2008;1:91-96
14. Renzi C, Tabolli S, Picardi A, Abeni D, Puddu P, Braga M. Effects of patient satisfaction with care on health-related quality of life: a prospective study. J Eur Acad Dermatol Venereol 2005;19:712-718 (Pubitemid 41743324)
15. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol 2006;5:527-532
16. Feldman SR, Brown KL, Heald P. 'Coral reef psoriasis: a marker of resistance to topical treatment. J Dermatolog Treat 2008;19:257-258
17. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009;8:52-57
18. Kimball AB, Gold MH, Zib B, Davis MW. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol 2008;59:448-54, 454.
19. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 2007;80:12-19
20. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-83 (Pubitemid 46908856)
21. Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de UP et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-463
22. Youssef RM, Mahgoub D, Mashaly HM, El-Nabarawy E, Samir N, El-Mofty M. Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed 2008;24:256-259
23. Han L, Somani AK, Huang Q, Fang X, Jin Y, Xiang LH et al. Evaluation of 308-nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis. Photodermatol Photoimmunol Photomed 2008;24:231-236
24. Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol 2009;23:36-41.
25. Yelverton CB, Yentzer BA, Clark A, Pearce DJ, Balkrishnan R, Camacho FT et al. Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis. Arch Dermatol 2008;144:1224-1225
26. Feldman SR, Clark A, Reboussin DM, Fleischer AB, Jr. An assessment of potential problems of home phototherapy treatment of psoriasis. Cutis 1996;58:71-73
27. Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface 2006;19:33-6, 39. (Pubitemid 43132600)
28. Yentzer BA, Yelverton CB, Pearce DJ, Camacho FT, Makhzoumi Z, Clark A et al. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol 2008;59:577-581
29. Su J, Pearce DJ, Feldman SR. The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatolog Treat 2005;16:324-326 (Pubitemid 43170203)
30. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR. Alternative therapies commonly used within a population of patients with psoriasis. Cutis 1996;58:216-220 (Pubitemid 26317973)
31. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008;128:1925-1929 (Pubitemid 352001201)
32. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005;152:954-960 (Pubitemid 40704936)
33. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008;300:537-44.
34. Reich K, Griffiths C, Barker J, Chimenti S, Dauden E, Giannetti A et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008;217:268-275
35. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes 2008;6:75.
36. Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007;18:25-31.
37. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
38. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007;127:1860-1867 (Pubitemid 47075365)
39. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009;160:438-441
40. Warren RB, Griffiths CE. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol 2005;153:869-873 (Pubitemid 41540748)
41. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-485 (Pubitemid 28125534)
42. MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol 2005;152:405-408 (Pubitemid 40547112)
43. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-450 (Pubitemid 40547117)
44. Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88:495-501.
45. Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M et al. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 2009;218:146-150
46. Warren EW, Khanderia U. Use of retinoids in the treatment of psoriasis. Clin Pharm 1989;8:344-351 (Pubitemid 19138080)
47. Leithead JA, Simpson KJ, Macgilchrist AJ. Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin. Eur J Gastroenterol Hepatol 2009. In press.
48. Huang W, Cordoro KM, Taylor SL, Feldman SR. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol 2008;58:970-977
49. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009;160:8-15.
50. Doherty SD, Van VA, Lebwohl MG, Korman NJ, Young MS, Hsu S et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008;59:209-217
51. Schlaak JF, Tully G, Lohr HF, Gerken G, Meyer zum Buschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999;115:508-514
52. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91. (Pubitemid 32368030)
53. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241-257 (Pubitemid 30337778)
54. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-217
55. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-1365 (Pubitemid 39120128)
56. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-687 (Pubitemid 36760576)
57. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003;30:1624-1625 (Pubitemid 36835467)
58. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-976
59. Montiel PM, Solis JA, Chirinos JA, Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20. (Pubitemid 351541107)
60. Zylberberg H, Rimaniol AC, Pol S, Masson A, De GD, Berthelot P et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999;30:185-191 (Pubitemid 29071178)
61. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-322 (Pubitemid 40254244)
62. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159:1217-1228
63. Mease PJ, Ory P, Sharp JT, Ritchlin CT, van den BF, Wellborne F et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2008.
64. Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009;160:380-386
65. Papp KA. Monitoring biologics for the treatment of psoriasis. Clin Dermatol 2008;26:515-521
66. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008;30:1939-1955
67. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006;298:7-15. (Pubitemid 43725207)
68. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-833 (Pubitemid 35403039)
69. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727
70. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255 (Pubitemid 32695064)
71. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53:73-75 (Pubitemid 40826697)
72. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-1068 (Pubitemid 350087341)
73. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J et al. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis. J Clin Pharmacol 2009;49:162-175
74. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674 (Pubitemid 351671883)
75. Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet 2008;371:1639-1640 (Pubitemid 351671871)
76. Griffiths C, Strober B, van de Kerkhof PC, Ho V, Guzzo C, Yeilding N et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe psoriasis. Presented at: 2008 European Academy of Dermatology & Venereology (EADV), Paris, Poster FP1336. 2008.
77. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207 (Pubitemid 351287002)
78. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007;143:1175-1179 (Pubitemid 47443371)
79. Warner J, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR. Using "number needed to treat" to help conceptualize the magnitude of benefit and risk of TNF-? inhibitors for patients with severe psoriasis. Br J Dermatol. 2009.
80. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741 (Pubitemid 44547793)
81. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
82. Kimball AB, Robinson D, Jr., Wu Y, Guzzo C, Yeilding N, Paramore C et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37.
83. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835 (Pubitemid 44556851)
84. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: an unsolved mystery. Am J Med 2008;121:360-5. (Pubitemid 351625996)
85. Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009;160:1-7.
86. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
87. Screening for depression: recommendations and rationale. Ann Intern Med 2002;136:760-764 (Pubitemid 34525676)
88. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-1042
89. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73. (Pubitemid 46934281)
90. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
91. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553
92. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:1631-1643
93. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304. (Pubitemid 16014779)
94. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986
95. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-1251 (Pubitemid 350115673)
96. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159:1331-1337
97. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988;91:197-201. (Pubitemid 18218499)
98. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-1675 (Pubitemid 47280349)
99. Murray ML, Bergstresser PR, ms-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol 2009;34:140-144
100. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571-1575
101. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207-1208
102. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008;159:820-826
103. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008;159:342-350 (Pubitemid 352009847)
104. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158:1134-1135
105. Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gomez-Reino J et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006;45:944-950
106. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15:2565-2571 (Pubitemid 33131083)
107. Sanna V, Di GA, La CA, Lechler RI, Fontana S, Zappacosta S et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111:241-250 (Pubitemid 36105923)
108. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 2001;54:347-354 (Pubitemid 32234199)
109. de Menezes Ettinger JE, Azaro E, de Souza CA, dos Santos Filho PV, Mello CA, Neves M, Jr. et al. Remission of psoriasis after open gastric bypass. Obes Surg 2006;16:94-97
110. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008;217:365-373
111. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006;67:768-773 (Pubitemid 44062144)
112. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006;290:E961-E967.
113. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007;25:606-615 (Pubitemid 350087607)
114. Kawamura A, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol 2003;13:406-407 (Pubitemid 36963106)
115. Wakefield PE, Berger TG, James WD. Atenolol-induced pustular psoriasis. Arch Dermatol 1990;126:968-969 (Pubitemid 20224565)
116. Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002;8:CR9-CR13. (Pubitemid 34136316)
117. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9. (Pubitemid 44908334)
118. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33-39 (Pubitemid 32121803)
119. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007;2007:78454. (Pubitemid 46198130)
120. Vahlquist C, Michaelsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987;67:12-15 (Pubitemid 17003486)
121. Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007;21:802-805 (Pubitemid 46939054)
122. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008;88:561-565
123. Naldi L, Parazzini F, Brevi A, Peserico A, Veller FC, Grosso G et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;127:212-217
124. McGinnis JM, Hamburg MA. Opportunities for health promotion and disease prevention in the clinical setting. West J Med 1988;149:468-474 (Pubitemid 18248967)
125. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-477 (Pubitemid 24204666)
126. Naldi L, Chatenoud L, Linder D, Belloni FA, Peserico A, Virgili AR et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67 (Pubitemid 40981424)
127. Mills CM, Srivastava ED, Harvey IM, Swift GL, Newcombe RG, Holt PJ et al. Smoking habits in psoriasis: a case control study. Br J Dermatol 1992;127:18-21.
128. Zhang X, Wang H, Te-Shao H, Yang S, Wang F. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int J Dermatol 2002;41:659-662 (Pubitemid 35252041)
129. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-1534
130. Braathen LR, Botten G, Bjerkedal T. Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl (Stockh) 1989;142:9-12.
131. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35. (Pubitemid 43038667)